Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2017

01-03-2017 | Review

The Quality of Care for Gastroesophageal Reflux Disease

Authors: Rena Yadlapati, Lara Dakhoul, John E. Pandolfino, Rajesh N. Keswani

Published in: Digestive Diseases and Sciences | Issue 3/2017

Login to get access

Abstract

Improving the quality of healthcare delivery is a cornerstone of modern medical care shared between all stakeholders. However, effectively improving quality requires both an understanding of the tenets of healthcare quality and how they relate to an individual disease process. This is especially important for common diseases, such as gastroesophageal reflux disease (GERD), where wide variations in practice exist. The high prevalence of GERD coupled with wide variation in clinical approach results in significant economic burden and poor quality of care. Thus, GERD serves as a useful framework to highlight the opportunities and current challenges of delivering high-quality care. In this article, we identify quality metrics in GERD and the areas in need of research to improve the quality of the management of GERD. Additionally, we suggest strategies for improvement as it relates to the proper diagnostic testing utilization and the decision-making process.
Literature
1.
go back to reference Blumenthal D, McGinnis JM. Measuring Vital Signs: an IOM report on core metrics for health and health care progress. JAMA. 2015;313:1901–1902.CrossRefPubMed Blumenthal D, McGinnis JM. Measuring Vital Signs: an IOM report on core metrics for health and health care progress. JAMA. 2015;313:1901–1902.CrossRefPubMed
2.
go back to reference Institute of Medicine Committee on Quality of Health Care in, A., in Crossing the Quality Chasm: A New Health System for the 21st Century. 2001, National Academies Press (US). Copyright 2001 by the National Academy of Sciences. All rights reserved. Washington, DC. Institute of Medicine Committee on Quality of Health Care in, A., in Crossing the Quality Chasm: A New Health System for the 21st Century. 2001, National Academies Press (US). Copyright 2001 by the National Academy of Sciences. All rights reserved. Washington, DC.
4.
go back to reference Jaspersen D. Extraesophageal manifestations in gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2006;52:269–274.PubMed Jaspersen D. Extraesophageal manifestations in gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2006;52:269–274.PubMed
5.
go back to reference Yadlapati R, Gawron AJ, Bilimoria K, et al. Development of quality measures for the care of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015;13:874–883.e2.CrossRef Yadlapati R, Gawron AJ, Bilimoria K, et al. Development of quality measures for the care of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015;13:874–883.e2.CrossRef
6.
go back to reference Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. (quiz 1943).CrossRefPubMed Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. (quiz 1943).CrossRefPubMed
7.
go back to reference Salyers WJ Jr, Mansour A, El-Haddad B, Golbeck AL, Kallail KJ. Lifestyle modification counseling in patients with gastroesophageal reflux disease. Gastroenterol Nurs. 2007;30:302–304.CrossRefPubMed Salyers WJ Jr, Mansour A, El-Haddad B, Golbeck AL, Kallail KJ. Lifestyle modification counseling in patients with gastroesophageal reflux disease. Gastroenterol Nurs. 2007;30:302–304.CrossRefPubMed
8.
go back to reference Blair DI, Kaplan B, Spiegler J. Patient characteristics and lifestyle recommendations in the treatment of gastroesophageal reflux disease. J Fam Pract. 1997;44:266–272.PubMed Blair DI, Kaplan B, Spiegler J. Patient characteristics and lifestyle recommendations in the treatment of gastroesophageal reflux disease. J Fam Pract. 1997;44:266–272.PubMed
9.
go back to reference Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14:175–182.CrossRefPubMed Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14:175–182.CrossRefPubMed
10.
go back to reference De Groot NL, Burgerhart JS, Van De Meeberg PC, et al. Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2009;30:1091–1102.CrossRefPubMed De Groot NL, Burgerhart JS, Van De Meeberg PC, et al. Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2009;30:1091–1102.CrossRefPubMed
11.
go back to reference Finley K, Giannamore M, Bennett M, Hall L. Assessing the impact of lifestyle modification education on knowledge and behavior changes in gastroesophageal reflux disease patients on proton pump inhibitors. J Am Pharm Assoc. 2009;49:544–548.CrossRef Finley K, Giannamore M, Bennett M, Hall L. Assessing the impact of lifestyle modification education on knowledge and behavior changes in gastroesophageal reflux disease patients on proton pump inhibitors. J Am Pharm Assoc. 2009;49:544–548.CrossRef
12.
go back to reference Dibley LB, Norton C, Jones R. Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care. Br J Gen Pract. 2010;60:e459–e465.CrossRefPubMedPubMedCentral Dibley LB, Norton C, Jones R. Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care. Br J Gen Pract. 2010;60:e459–e465.CrossRefPubMedPubMedCentral
13.
go back to reference Johnson NB, Jayes LD, Brown K, et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors: United States, 2005–2013. MMWR. 2014;63:3–27. Johnson NB, Jayes LD, Brown K, et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors: United States, 2005–2013. MMWR. 2014;63:3–27.
14.
go back to reference Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity. 2013;21:284–290.CrossRefPubMed Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity. 2013;21:284–290.CrossRefPubMed
15.
17.
go back to reference Gawron AJ, French DD, Pandolfino JE, Howden CW. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics. 2014;32:745–758.CrossRefPubMedPubMedCentral Gawron AJ, French DD, Pandolfino JE, Howden CW. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics. 2014;32:745–758.CrossRefPubMedPubMedCentral
18.
go back to reference Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25:1869–1878.CrossRefPubMed Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25:1869–1878.CrossRefPubMed
19.
go back to reference Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefPubMed Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefPubMed
20.
go back to reference Gawron AJ, Rothe J, Fought AJ, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10:620–625. (quiz e57).CrossRefPubMedPubMedCentral Gawron AJ, Rothe J, Fought AJ, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10:620–625. (quiz e57).CrossRefPubMedPubMedCentral
21.
go back to reference Eherer AJ, Netolitzky F, Hogenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol. 2012;107:372–378.CrossRefPubMed Eherer AJ, Netolitzky F, Hogenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol. 2012;107:372–378.CrossRefPubMed
23.
go back to reference Cote GA, Ferreira MR, Rozenberg-Ben-Dror K, Howden CW. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment Pharmacol Ther. 2007;25:709–714.CrossRefPubMed Cote GA, Ferreira MR, Rozenberg-Ben-Dror K, Howden CW. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment Pharmacol Ther. 2007;25:709–714.CrossRefPubMed
24.
go back to reference Gawron AJ, Pandolfino JE. Ambulatory reflux monitoring in GERD—which test should be performed and should therapy be stopped? Curr Gastroenterol Rep. 2013;15:316.CrossRefPubMedPubMedCentral Gawron AJ, Pandolfino JE. Ambulatory reflux monitoring in GERD—which test should be performed and should therapy be stopped? Curr Gastroenterol Rep. 2013;15:316.CrossRefPubMedPubMedCentral
26.
go back to reference Tan J, Wang Y, Sun X, et al. The effect of Helicobacter pylori eradication therapy on the development of gastroesophageal reflux disease. Am J Med Sci. 2015;349:364–371.CrossRefPubMed Tan J, Wang Y, Sun X, et al. The effect of Helicobacter pylori eradication therapy on the development of gastroesophageal reflux disease. Am J Med Sci. 2015;349:364–371.CrossRefPubMed
27.
go back to reference Wang XT, Zhang M, Chen CY, et al. Helicobacter pylori eradication and gastroesophageal reflux disease: a meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55:710–716.PubMed Wang XT, Zhang M, Chen CY, et al. Helicobacter pylori eradication and gastroesophageal reflux disease: a meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55:710–716.PubMed
28.
go back to reference Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157:808–816.CrossRefPubMed Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157:808–816.CrossRefPubMed
29.
go back to reference Zamosky L. GERD: rising healthcare costs spark new debate, guidelines. Revised standards designed to save system money, prevent overuse of diagnostics. Med Econ. 2013;90:48–50.PubMed Zamosky L. GERD: rising healthcare costs spark new debate, guidelines. Revised standards designed to save system money, prevent overuse of diagnostics. Med Econ. 2013;90:48–50.PubMed
30.
go back to reference Park WG, Shaheen NJ, Cohen J, et al. Quality indicators for EGD. Gastrointest Endosc. 2015;81:17–30.CrossRefPubMed Park WG, Shaheen NJ, Cohen J, et al. Quality indicators for EGD. Gastrointest Endosc. 2015;81:17–30.CrossRefPubMed
31.
go back to reference Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–1413.CrossRefPubMed Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–1413.CrossRefPubMed
32.
go back to reference Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–328. (quiz 329).CrossRefPubMed Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–328. (quiz 329).CrossRefPubMed
33.
go back to reference Allen JI. Endoscopy for gastroesophageal reflux disease: choose wisely. Ann Intern Med. 2012;157:827–828.CrossRefPubMed Allen JI. Endoscopy for gastroesophageal reflux disease: choose wisely. Ann Intern Med. 2012;157:827–828.CrossRefPubMed
34.
go back to reference Kleiman DA, Zarnegar R. An old tool may fix a new problem: early utilization of 24-h esophageal pH monitoring may reduce unnecessary proton-pump inhibitor use and improve outcomes. J Comp Eff Res. 2013;2:409–411.CrossRefPubMed Kleiman DA, Zarnegar R. An old tool may fix a new problem: early utilization of 24-h esophageal pH monitoring may reduce unnecessary proton-pump inhibitor use and improve outcomes. J Comp Eff Res. 2013;2:409–411.CrossRefPubMed
35.
go back to reference Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.CrossRefPubMed Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.CrossRefPubMed
36.
go back to reference Kessing BF, Bredenoord AJ, Smout AJ. The pathophysiology, diagnosis and treatment of excessive belching symptoms. Am J Gastroenterol. 2014;109:1196–1203. (quiz 1204).CrossRefPubMed Kessing BF, Bredenoord AJ, Smout AJ. The pathophysiology, diagnosis and treatment of excessive belching symptoms. Am J Gastroenterol. 2014;109:1196–1203. (quiz 1204).CrossRefPubMed
37.
go back to reference Broeders JA, Bredenoord AJ, Hazebroek EJ, et al. Effects of anti-reflux surgery on weakly acidic reflux and belching. Gut. 2011;60:435–441.CrossRefPubMed Broeders JA, Bredenoord AJ, Hazebroek EJ, et al. Effects of anti-reflux surgery on weakly acidic reflux and belching. Gut. 2011;60:435–441.CrossRefPubMed
38.
go back to reference Desjardin M, Luc G, Collet D, Zerbib F. 24-hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Neurogastroenterol Motil. 2016;28:146–152.CrossRefPubMed Desjardin M, Luc G, Collet D, Zerbib F. 24-hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Neurogastroenterol Motil. 2016;28:146–152.CrossRefPubMed
39.
go back to reference Frazzoni M, Piccoli M, Conigliaro R, et al. Refractory gastroesophageal reflux disease as diagnosed by impedance-pH monitoring can be cured by laparoscopic fundoplication. Surg Endosc. 2013;27:2940–2946.CrossRefPubMed Frazzoni M, Piccoli M, Conigliaro R, et al. Refractory gastroesophageal reflux disease as diagnosed by impedance-pH monitoring can be cured by laparoscopic fundoplication. Surg Endosc. 2013;27:2940–2946.CrossRefPubMed
40.
go back to reference Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006;93:1483–1487.CrossRefPubMed Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006;93:1483–1487.CrossRefPubMed
41.
go back to reference Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3:329–334.CrossRefPubMed Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3:329–334.CrossRefPubMed
42.
go back to reference Prakash C, Clouse RE. Wireless pH monitoring in patients with non-cardiac chest pain. Am J Gastroenterol. 2006;101:446–452.CrossRefPubMed Prakash C, Clouse RE. Wireless pH monitoring in patients with non-cardiac chest pain. Am J Gastroenterol. 2006;101:446–452.CrossRefPubMed
43.
go back to reference Radaelli F, Strocchi E, Passaretti S, et al. Is esophageal pH monitoring used appropriately in an open-access system? A prospective multicenter study. Am J Gastroenterol. 2004;99:2115–2120.CrossRefPubMed Radaelli F, Strocchi E, Passaretti S, et al. Is esophageal pH monitoring used appropriately in an open-access system? A prospective multicenter study. Am J Gastroenterol. 2004;99:2115–2120.CrossRefPubMed
44.
go back to reference Ali MA, Lacy BE. Esophageal manometry and pH monitoring: gastroenterologists’ adherence to published guidelines. J Clin Gastroenterol. 2005;39:584–590.CrossRefPubMed Ali MA, Lacy BE. Esophageal manometry and pH monitoring: gastroenterologists’ adherence to published guidelines. J Clin Gastroenterol. 2005;39:584–590.CrossRefPubMed
45.
go back to reference Ashfaq A, Rhee HK, Harold KL. Revision of failed transoral incisionless fundoplication by subsequent laparoscopic Nissen fundoplication. World J Gastroenterol. 2014;20:17115–17119.CrossRefPubMedPubMedCentral Ashfaq A, Rhee HK, Harold KL. Revision of failed transoral incisionless fundoplication by subsequent laparoscopic Nissen fundoplication. World J Gastroenterol. 2014;20:17115–17119.CrossRefPubMedPubMedCentral
46.
go back to reference Varban OA, McCoy TP, Westcott C. A comparison of pre-operative comorbidities and post-operative outcomes among patients undergoing laparoscopic nissen fundoplication at high- and low-volume centers. J Gastrointest Surg. 2011;15:1121–1127.CrossRefPubMed Varban OA, McCoy TP, Westcott C. A comparison of pre-operative comorbidities and post-operative outcomes among patients undergoing laparoscopic nissen fundoplication at high- and low-volume centers. J Gastrointest Surg. 2011;15:1121–1127.CrossRefPubMed
47.
go back to reference Ingraham AM, Richards KE, Hall BL, et al. Quality improvement in surgery: the American College of Surgeons national surgical quality improvement program approach. Adv Surg. 2010;44:251–267.CrossRefPubMed Ingraham AM, Richards KE, Hall BL, et al. Quality improvement in surgery: the American College of Surgeons national surgical quality improvement program approach. Adv Surg. 2010;44:251–267.CrossRefPubMed
48.
go back to reference Sherman KL, Gordon EJ, Mahvi DM, et al. Surgeons’ perceptions of public reporting of hospital and individual surgeon quality. Med Care. 2013;51:1069–1075.CrossRefPubMed Sherman KL, Gordon EJ, Mahvi DM, et al. Surgeons’ perceptions of public reporting of hospital and individual surgeon quality. Med Care. 2013;51:1069–1075.CrossRefPubMed
49.
go back to reference Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastrooesophageal reflux disease (GORD) in adults. Cochrane database Syst Rev. 2015;11:CD003243. doi:10.1002/14651858.CD003243.pub3. Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastrooesophageal reflux disease (GORD) in adults. Cochrane database Syst Rev. 2015;11:CD003243. doi:10.​1002/​14651858.​CD003243.​pub3.
50.
51.
go back to reference Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. J Clin Gastroenterol. 2014;48:584–589.CrossRefPubMed Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. J Clin Gastroenterol. 2014;48:584–589.CrossRefPubMed
52.
go back to reference Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:1058–1067.CrossRefPubMed Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:1058–1067.CrossRefPubMed
53.
go back to reference Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11:465–471. (quiz e39).CrossRefPubMed Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11:465–471. (quiz e39).CrossRefPubMed
54.
go back to reference Kamolz T, Pointner R. Expectations of patients with gastroesophageal reflux disease for the outcome of laparoscopic antireflux surgery. Surg Laparosc Endosc Percutan Tech. 2002;12:389–392.CrossRefPubMed Kamolz T, Pointner R. Expectations of patients with gastroesophageal reflux disease for the outcome of laparoscopic antireflux surgery. Surg Laparosc Endosc Percutan Tech. 2002;12:389–392.CrossRefPubMed
55.
go back to reference Stanghellini V, Armstrong D, Mönnikes H, et al. Determination of ReQuest™-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2007;75:55–61.CrossRefPubMed Stanghellini V, Armstrong D, Mönnikes H, et al. Determination of ReQuest™-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2007;75:55–61.CrossRefPubMed
56.
go back to reference Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:905–911.CrossRefPubMed Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:905–911.CrossRefPubMed
58.
go back to reference Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope. 2001;111:2147–2151.CrossRefPubMed Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope. 2001;111:2147–2151.CrossRefPubMed
59.
go back to reference El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001;96:979–983.CrossRefPubMed El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001;96:979–983.CrossRefPubMed
60.
go back to reference Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg. 2004;131:342–350.CrossRefPubMed Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg. 2004;131:342–350.CrossRefPubMed
61.
go back to reference Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2013;42:71–91.CrossRefPubMed Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2013;42:71–91.CrossRefPubMed
62.
go back to reference Yadlapati R, Adkins C, Jaiyeola DM, et al. Abilities of oropharyngeal pH tests and salivary pepsin analysis to discriminate between asymptomatic volunteers and subjects with symptoms of laryngeal irritation. Clin Gastroenterol Hepatol. 2016;14:535–542.CrossRefPubMed Yadlapati R, Adkins C, Jaiyeola DM, et al. Abilities of oropharyngeal pH tests and salivary pepsin analysis to discriminate between asymptomatic volunteers and subjects with symptoms of laryngeal irritation. Clin Gastroenterol Hepatol. 2016;14:535–542.CrossRefPubMed
63.
go back to reference Yadlapati R, Pandolfino JE, Lidder AK, et al. Oropharyngeal pH testing does not predict response to proton pump inhibitor therapy in patients with laryngeal symptoms. Am J Gastroenterol. 2016;111:1517–1524.CrossRefPubMedPubMedCentral Yadlapati R, Pandolfino JE, Lidder AK, et al. Oropharyngeal pH testing does not predict response to proton pump inhibitor therapy in patients with laryngeal symptoms. Am J Gastroenterol. 2016;111:1517–1524.CrossRefPubMedPubMedCentral
64.
go back to reference Armstrong D, Marshall JK, Chiba N, et al. Canadian consensus conference on the management of gastroesophageal reflux disease in adults: update 2004. Can J Gastroenterol. 2005;19:15–35.CrossRefPubMed Armstrong D, Marshall JK, Chiba N, et al. Canadian consensus conference on the management of gastroesophageal reflux disease in adults: update 2004. Can J Gastroenterol. 2005;19:15–35.CrossRefPubMed
Metadata
Title
The Quality of Care for Gastroesophageal Reflux Disease
Authors
Rena Yadlapati
Lara Dakhoul
John E. Pandolfino
Rajesh N. Keswani
Publication date
01-03-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4409-6

Other articles of this Issue 3/2017

Digestive Diseases and Sciences 3/2017 Go to the issue

REVIEWER ACKNOWLEDGMENT

Acknowledgment of 2016 Reviewers

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.